Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.
Shanghai Junshi Biosciences Co., Ltd. has announced its 2024 Annual General Meeting to be held in June 2025, where several key proposals will be discussed. These include the approval of financial reports, profit distribution plans, and the issuance of debt financing instruments up to RMB2,500 million to support business development and reduce financing costs, reflecting the company’s strategic focus on leveraging market opportunities.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in China, operating in the biosciences industry. The company focuses on developing and providing innovative therapeutic products, with a market focus on both domestic and international healthcare sectors.
Average Trading Volume: 2,963,762
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.72B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue